	销售和管理费用		日
AbbVie	USD 3.63B	54M	2026-06
Amgen	USD 1.72B	134M	2026-06
Anika Therapeutics	USD 10.01M	14K	2025-12
Arrowhead Research	USD 46.63M	4.88M	2026-06
AstraZeneca	USD 5.8B	735M	2026-06
BioCryst Pharmaceuticals	USD 63.98M	31.8M	2026-06
Biogen	USD 709.7M	155.4M	2026-06
Bristol-Myers Squibb	USD 1.83B	209M	2026-06
Enanta Pharmaceuticals	USD -1.05	0.31	2024-12
Gilead Sciences	USD 1.52B	70M	2026-06
GlaxoSmithKline	GBP 2.19B	75M	2026-06
Halozyme Therapeutics	USD 57M	10.71M	2026-06
Heron Therapeutics	USD 23.74M	605K	2025-12
Immunic	USD 3.45M	451K	2025-12
Incyte	USD 351.73M	23.64M	2026-06
Insmed	USD 247.47M	208K	2026-06
Ionis Pharmaceuticals	USD 130.07M	20.92M	2026-06
J&J	USD 6.42B	381M	2026-06
Karyopharm Therapeutics	USD 10.42M	861K	2026-03
Ligand Pharmaceuticals	USD 29.12M	8.29M	2026-06
Merck	USD 2.89B	219M	2026-06
Neurocrine Biosciences	USD 383.1M	64.6M	2026-06
Novartis	USD 3.24B	101M	2026-06
Novavax	USD 25.53M	1.34M	2025-12
Pfizer	USD 3.41B	496M	2026-06
PTC Therapeutics	USD 73.89M	13.31M	2026-03
Roche Holding	CHF 6.37B	908M	2026-06
Sarepta Therapeutics	USD 107.6M	53.57M	2026-06
Vertex Pharmaceuticals	USD 582.2M	88.5M	2026-06